DGIdb - NF1 Gene Record

NF1 4763 Clinically ActionableDrug Resistance

Alternate Names:

4763
NEUROFIBROMIN 1
NF1
NFNS
VRNF
WSS
613113
7765
ENSG00000196712
OTTHUMG00000132871
3867

Gene Info:

Gene Biotype	PROTEIN_CODING

(6 More Sources)

Gene Categories: Category Details

DRUG RESISTANCE
CLINICALLY ACTIONABLE

Publications:

Woodfield et al., 2016, Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression., BMC Cancer
Dombi et al., 2016, Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas., N. Engl. J. Med.
Fangusaro J et al., 2019, Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial., Lancet Oncol
Lim et al., 2016, Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus., Oncotarget
Raushenbakh et al., 1976, [Induction of tyrosine aminotransferase by blastomogenic metabolites of tryptophan and tyrosine]., Biull Eksp Biol Med
Kahn et al., 1975, Effect of sodium nitrate loading on electrolyte transport by the renal tubule., Am. J. Physiol.
Agarwal et al., 1976, A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris., J. Int. Med. Res.
Silen et al., 1975, Acid-base balance in amphibian gastric mucosa., Am. J. Physiol.
Nissan et al., 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence., Cancer Res.
Hayashi T et al., 2018, <i>RASA1</i> and <i>NF1</i> are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition., Clin Cancer Res
Winoto et al., 1989, A novel, inducible and T cell-specific enhancer located at the 3' end of the T cell receptor alpha locus., EMBO J.
Avery et al., 2014, Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab., JAMA Ophthalmol
Bague-Liebert, 1989, [Prevention ... I am positive. Interview with M.E. Bague-Liebert). Interview by Nadine Wehvlin]., Rev Infirm
Whittaker et al., 2013, A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition., Cancer Discov
Savarese et al., beta-Adrenergic receptor decrease in diabetic rat hearts., Life Sci.
Maertens et al., 2013, Elucidating distinct roles for NF1 in melanomagenesis., Cancer Discov

TIPIFARNIB NF1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Farnesyltransferase inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
TRAMETINIB NF1

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration NF1:.

Drug family MEK inhibitor

Alteration NF1:del

PMIDs:
24576830 29127119 2524381

Sources:
ClearityFoundationBiomarkers OncoKB CIViC CGI
EVEROLIMUS NF1

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MTOR inhibitor;VEGFR inhibitor

combination therapy Everolimus;Pazopanib

Drug family MTOR inhibitor;EGFR inhibitor 1st gen

PMIDs:
26859683 11010 2016 17557 2015

Sources:
CGI
COBIMETINIB NF1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers OncoKB
SELUMETINIB NF1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MEK inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
28029918 31151904

Sources:
ClearityFoundationBiomarkers CIViC CGI
BINIMETINIB NF1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26925841

Sources:
ClearityFoundationBiomarkers CIViC
VEMURAFENIB NF1

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BRAF inhibitor

Alteration NF1:.

Alteration NF1:del;BRAF:.

PMIDs:
23288408 231718

Sources:
CIViC CGI
PIMASERTIB NF1

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
DABRAFENIB NF1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23171796

Sources:
CIViC
NILOTINIB NF1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 2nd gen

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
PEXIDARTINIB NF1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Pan-TK inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
BEVACIZUMAB NF1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration NF1:.

Alteration NF1:del

Drug family VEGFR mAb inhibitor

PMIDs:
24232489 2485933

Sources:
CGI
SIROLIMUS NF1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MTOR inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
23171796

Sources:
CIViC CGI
VINBLASTINE NF1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy;BCR-ABL inhibitor 2nd gen

combination therapy Vinblastine;Nilotinib

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
PAZOPANIB NF1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Pazopanib

Drug family MTOR inhibitor;VEGFR inhibitor

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
CEDIRANIB NF1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family ALK inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
ERLOTINIB NF1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family EGFR inhibitor 1st gen

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
TAMOXIFEN NF1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration NF1:.

Alteration NF1:del

Drug family Hormonal therapy

PMIDs:
None found

Sources:
CGI
IMATINIB NF1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 1st gen&KIT inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
DASATINIB NF1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 2nd gen

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
SORAFENIB NF1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sorafenib;Sirolimus

Drug family Pan-TK inhibitor;MTOR inhibitor

Alteration NF1:del

PMIDs:
None found

Sources:
CGI

Ensembl: ENSG00000196712
- Version: 101_38
Alternate Names:

NF1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

CIViC: NF1

Version: 14-September-2020

Alternate Names:

4763 Entrez Gene ID

3867 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Maertens et al., 2013, Elucidating distinct roles for NF1 in melanomagenesis., Cancer Discov

Dombi et al., 2016, Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas., N. Engl. J. Med.

Fangusaro J et al., 2019, Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial., Lancet Oncol

CGI: NF1

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Avery et al., 2014, Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab., JAMA Ophthalmol

Bague-Liebert, 1989, [Prevention ... I am positive. Interview with M.E. Bague-Liebert). Interview by Nadine Wehvlin]., Rev Infirm

Lim et al., 2016, Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus., Oncotarget

OncoKB: NF1
- Version: 23-July-2020
Alternate Names:

4763 OncoKB Entrez Id

WSS OncoKB Gene Synonym

NFNS OncoKB Gene Synonym

Gene Info:

Publications:
Tempus: NF1
- Version: 11-November-2018
Alternate Names:

NF1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
ClearityFoundationBiomarkers: NF1
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:
MskImpact: NF1
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: NF1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: NF1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: NF1
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Drug family	Farnesyltransferase inhibitor
Alteration	NF1:del
Alteration	NF1:.

Drug family	MTOR inhibitor;VEGFR inhibitor
combination therapy	Everolimus;Pazopanib
Drug family	MTOR inhibitor;EGFR inhibitor 1st gen

Drug family	BRAF inhibitor
Alteration	NF1:.
Alteration	NF1:del;BRAF:.

Drug family	BCR-ABL inhibitor 2nd gen
Alteration	NF1:del
Alteration	NF1:.

Drug family	Chemotherapy;BCR-ABL inhibitor 2nd gen
combination therapy	Vinblastine;Nilotinib
Alteration	NF1:.

Drug family	EGFR inhibitor 1st gen
Alteration	NF1:del
Alteration	NF1:.

Drug family	BCR-ABL inhibitor 1st gen&KIT inhibitor
Alteration	NF1:del
Alteration	NF1:.

combination therapy	Sorafenib;Sirolimus
Drug family	Pan-TK inhibitor;MTOR inhibitor
Alteration	NF1:del

4763	OncoKB Entrez Id
WSS	OncoKB Gene Synonym
NFNS	OncoKB Gene Synonym

NF1 Gene Record

NF1 4763 Clinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Drug family Farnesyltransferase inhibitor Alteration NF1:del Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Alteration NF1:. Drug family MEK inhibitor Alteration NF1:del

PMIDs: 24576830 29127119 2524381

Sources: ClearityFoundationBiomarkers OncoKB CIViC CGI

Interaction Types & Directionality: n/a

Interaction Info: Drug family MTOR inhibitor;VEGFR inhibitor combination therapy Everolimus;Pazopanib Drug family MTOR inhibitor;EGFR inhibitor 1st gen

PMIDs: 26859683 11010 2016 17557 2015

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Drug family MEK inhibitor Alteration NF1:del Alteration NF1:.

PMIDs: 28029918 31151904

Sources: ClearityFoundationBiomarkers CIViC CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26925841

Sources: ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality: n/a

Interaction Info: Drug family BRAF inhibitor Alteration NF1:. Alteration NF1:del;BRAF:.

PMIDs: 23288408 231718

Sources: CIViC CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23171796

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Drug family BCR-ABL inhibitor 2nd gen Alteration NF1:del Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Drug family Pan-TK inhibitor Alteration NF1:del Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Alteration NF1:. Alteration NF1:del Drug family VEGFR mAb inhibitor

PMIDs: 24232489 2485933

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Drug family MTOR inhibitor Alteration NF1:del Alteration NF1:.

PMIDs: 23171796

Sources: CIViC CGI

Interaction Types & Directionality: n/a

Interaction Info: Drug family Chemotherapy;BCR-ABL inhibitor 2nd gen combination therapy Vinblastine;Nilotinib Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Everolimus;Pazopanib Drug family MTOR inhibitor;VEGFR inhibitor Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Drug family ALK inhibitor Alteration NF1:del Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Drug family EGFR inhibitor 1st gen Alteration NF1:del Alteration NF1:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Alteration NF1:. Alteration NF1:del Drug family Hormonal therapy

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: Drug family BCR-ABL inhibitor 1st gen&KIT inhibitor Alteration NF1:del Alteration NF1:.

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Farnesyltransferase inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration NF1:.

Drug family MEK inhibitor

Alteration NF1:del

PMIDs:
24576830 29127119 2524381

Sources:
ClearityFoundationBiomarkers OncoKB CIViC CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MTOR inhibitor;VEGFR inhibitor

combination therapy Everolimus;Pazopanib

Drug family MTOR inhibitor;EGFR inhibitor 1st gen

PMIDs:
26859683 11010 2016 17557 2015

Sources:
CGI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MEK inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
28029918 31151904

Sources:
ClearityFoundationBiomarkers CIViC CGI

Interaction Types & Directionality:

n/a

PMIDs:
26925841

Sources:
ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BRAF inhibitor

Alteration NF1:.

Alteration NF1:del;BRAF:.

PMIDs:
23288408 231718

Sources:
CIViC CGI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

PMIDs:
23171796

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 2nd gen

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Pan-TK inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration NF1:.

Alteration NF1:del

Drug family VEGFR mAb inhibitor

PMIDs:
24232489 2485933

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family MTOR inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
23171796

Sources:
CIViC CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy;BCR-ABL inhibitor 2nd gen

combination therapy Vinblastine;Nilotinib

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus;Pazopanib

Drug family MTOR inhibitor;VEGFR inhibitor

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family ALK inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family EGFR inhibitor 1st gen

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration NF1:.

Alteration NF1:del

Drug family Hormonal therapy

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 1st gen&KIT inhibitor

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 2nd gen

Alteration NF1:del

Alteration NF1:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sorafenib;Sirolimus

Drug family Pan-TK inhibitor;MTOR inhibitor

Alteration NF1:del

PMIDs:
None found

Sources:
CGI